Skip to content

Debt-to-equity at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
0.0×
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
0.1×-0.1×
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
1.4×+1.1×
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
0.0×
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
0.0×
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
0.9×-5.1×

Other financials

Income statement

See full
Revenue$214.3M+55.5%
Gross profit$193.5M+61.3%
Operating income$29.3M+121%
Net income$22.6M+165%
EPS (diluted)$0.27+145%

Balance sheet

See full
Cash & equivalents$190.0M+20.9%
Total debt$9.0M-9.0%
Total equity$605.7M+32.4%
Total assets$825.3M+37.7%

Cash flow

See full
Operating cash flow$50.2M+125%
CapEx$161.0K+62.6%
Free cash flow$50.0M+125%

Valuation

See full
Market cap$4.24B+128%
Enterprise value$4.06B+139%
P/E58×
P/S5.6×+1.8×

Profitability

See full
Gross margin89.3%+3.5pp
Operating margin12.4%+10.2pp
Net margin9.7%+7.6pp
FCF margin21.8%+12.2pp

Returns & leverage

See full
Return on equity13.7%+11.3pp
Current ratio3.8×+0.1×

Where this comes from

Calculated from Kiniksa Pharmaceuticals International, plc’s reported figures.

Based on the most recent quarter.

The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kiniksa Pharmaceuticals International, plc's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kiniksa Pharmaceuticals International, plc's debt-to-equity?
Kiniksa Pharmaceuticals International, plc (KNSA) reported debt-to-equity of 0× in Q1 2026.
How has Kiniksa Pharmaceuticals International, plc's debt-to-equity changed year-over-year?
Kiniksa Pharmaceuticals International, plc's debt-to-equity decreased by 31.3% year-over-year, from 0× to 0×.
What is the long-term trend for Kiniksa Pharmaceuticals International, plc's debt-to-equity?
Over 5 years (2020 to 2025), Kiniksa Pharmaceuticals International, plc's debt-to-equity has grown at a -5.7% compound annual growth rate (CAGR), from 0× to 0×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.